Company record · updated August 5, 2026
Vera Therapeutics, Inc.: 5 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs April 23, 2021 to May 10, 2021.
5observations
2source filings
5verified rows
2021-05-10most recent as-of date
Source rails for this company: S-1 charter round (5).
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2021-05-10 | Series SEED price per share | 1.0095 USD | — | VERIFIED | "Original Issue Price" defined for Series SEED | 000119312521155556 |
| 2021-05-10 | Series C price per share | 0.5918 USD | — | VERIFIED | "Original Issue Price" defined for Series C | 000119312521155556 |
| 2021-05-10 | Series B price per share | 4.2926 USD | — | VERIFIED | "Original Issue Price" defined for Series B | 000119312521155556 |
| 2021-05-10 | Series A price per share | 2.1463 USD | — | VERIFIED | "Original Issue Price" defined for Series A | 000119312521155556 |
| 2021-04-23 | Series C price per share | 500 USD | — | VERIFIED | "Original Issue Price" defined for Series C | 000119312521129272 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.